Measuring the impact of pharmacovigilance activities, challenging but important.
作者信息
van Hunsel Florence, Gardarsdottir Helga, de Boer Anthonius, Kant Agnes
机构信息
Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands.
Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
出版信息
Br J Clin Pharmacol. 2019 Oct;85(10):2235-2237. doi: 10.1111/bcp.14042. Epub 2019 Jul 31.
Abstract
摘要
相似文献
1
Measuring the impact of pharmacovigilance activities, challenging but important.衡量药物警戒活动的影响，具有挑战性但很重要。
Br J Clin Pharmacol. 2019 Oct;85(10):2235-2237. doi: 10.1111/bcp.14042. Epub 2019 Jul 31.
2
Improving the Safety of Medicines in the European Union: From Signals to Action.提高欧盟药品安全性：从信号到行动。
Clin Pharmacol Ther. 2020 Mar;107(3):521-529. doi: 10.1002/cpt.1678. Epub 2019 Dec 6.
3
Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study.向荷兰国家药物警戒中心报告的药物不良反应中的性别差异：一项探索性观察研究。
Br J Clin Pharmacol. 2019 Jul;85(7):1507-1515. doi: 10.1111/bcp.13923. Epub 2019 Apr 29.
4
Current trends in pharmacovigilance: value and gaps of patient reporting.药物警戒的当前趋势：患者报告的价值与差距
Int J Clin Pharm. 2018 Aug;40(4):754-757. doi: 10.1007/s11096-018-0689-6. Epub 2018 Jul 13.
5
A review of the National pharmacovigilance system in Malta - implementing and operating a pharmacovigilance management system.马耳他国家药物警戒系统综述——实施和运营药物警戒管理系统
Expert Opin Drug Saf. 2017 Jan;16(1):65-76. doi: 10.1080/14740338.2017.1247806. Epub 2016 Oct 24.
6
[From pharmacovigilance to pharmacoepidemiology and risk coordination].从药物警戒到药物流行病学与风险协调
Rev Med Interne. 2009 Dec;30 Suppl 4:S281-90. doi: 10.1016/j.revmed.2009.07.004. Epub 2009 Nov 4.
7
Towards Drug Safety Surveillance and Pharmacovigilance: Current Progress in Detecting Medication and Adverse Drug Events from Electronic Health Records.迈向药物安全监测与药物警戒：从电子健康记录中检测用药及药物不良事件的当前进展
Drug Saf. 2019 Jan;42(1):95-97. doi: 10.1007/s40264-018-0766-8.
8
The value of patient reporting to the pharmacovigilance system: a systematic review.患者向药物警戒系统报告的价值：一项系统评价
Br J Clin Pharmacol. 2017 Feb;83(2):227-246. doi: 10.1111/bcp.13098. Epub 2016 Oct 12.
9
Adverse drug reactions in neonates: could we be documenting more?新生儿的药物不良反应：我们是否能记录得更多？
Expert Rev Clin Pharmacol. 2014 Nov;7(6):807-20. doi: 10.1586/17512433.2014.956090. Epub 2014 Sep 16.
10
Pharmacovigilance in Europe.欧洲的药物警戒
Transplantation. 2015 Aug;99(8):1542-3. doi: 10.1097/TP.0000000000000862.
引用本文的文献
1
Impact of Regulatory Action on Dose Maximalization for Vitamin B6 Dietary Supplements on the Reporting Pattern for Neuropathy.监管行动对维生素B6膳食补充剂剂量最大化的影响及其对神经病变报告模式的作用。
Pharmacoepidemiol Drug Saf. 2025 Feb;34(2):e70108. doi: 10.1002/pds.70108.
2
Cross-sectional study of pharmacovigilance knowledge, attitudes, and practices based on structural equation modeling and network analysis: a case study of healthcare personnel and the public in Yunnan Province.基于结构方程模型和网络分析的药物警戒知识、态度和实践的横断面研究：云南省医护人员和公众的案例研究。
Front Public Health. 2024 Mar 19;12:1358117. doi: 10.3389/fpubh.2024.1358117. eCollection 2024.
3
Evolution of the profiles of new psychotropic drug users before and during the COVID-19 crisis: an original longitudinal approach through multichannel sequence analysis using the French health-care database.新冠疫情危机之前及期间新型精神药物使用者概况的演变：一种通过使用法国医疗保健数据库的多通道序列分析进行的原创纵向研究方法。
Eur Arch Psychiatry Clin Neurosci. 2024 Mar 18. doi: 10.1007/s00406-024-01774-3.
4
Appeal for Increasing the Impact of Pharmacovigilance.呼吁提高药物警戒的影响力。
Drug Saf. 2024 Feb;47(2):113-116. doi: 10.1007/s40264-023-01375-4. Epub 2023 Dec 20.
5
The effect of clinical pharmacists' intervention in adverse drug reaction reporting: a retrospective analysis with a 9-year interrupted time series.临床药师干预药物不良反应报告的效果：一项 9 年中断时间序列的回顾性分析。
BMC Health Serv Res. 2022 Jul 19;22(1):925. doi: 10.1186/s12913-022-08320-8.
6
Pharmacovigilance in China: Evolution and future challenges.中国的药物警戒：演变与未来挑战。
Br J Clin Pharmacol. 2023 Feb;89(2):510-522. doi: 10.1111/bcp.15277. Epub 2022 Mar 16.
7
Assessing the Impact on Health of Pharmacovigilance Activities: Example of Four Safety Signals.评估药物警戒活动对健康的影响：四个安全信号示例
Drug Saf. 2021 May;44(5):589-600. doi: 10.1007/s40264-021-01047-1. Epub 2021 Feb 19.
8
Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET).从使用新型利益相关者安全参与工具（ASSET）对欧盟丙戊酸盐评估中利益相关者投入的分析中得出的关于使患者和医疗保健专业人员参与风险最小化的建议。
Drug Saf. 2021 Feb;44(2):193-209. doi: 10.1007/s40264-020-01005-3. Epub 2020 Oct 30.
9
Effect of pharmaceutical regulatory policy on health impact.药品监管政策对健康影响的作用
Br J Clin Pharmacol. 2020 Dec;86(12):2335-2337. doi: 10.1111/bcp.14390. Epub 2020 Jun 14.
本文引用的文献
1
Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation.欧洲的电子医疗保健数据库：特征描述及在药品监管中的应用潜力分析
BMJ Open. 2018 Sep 5;8(9):e023090. doi: 10.1136/bmjopen-2018-023090.
2
The use of complementary and alternative medicines during breastfeeding: results from the Herbal supplements in Breastfeeding InvesTigation (HaBIT) study.哺乳期使用补充剂和替代药物：母乳喂养调查（HaBIT）研究中的草药补充剂结果。
Br J Clin Pharmacol. 2018 Sep;84(9):2040-2047. doi: 10.1111/bcp.13639. Epub 2018 Jul 3.
3
Listen to the public and fulfil their information interests - translating vaccine communication research findings into guidance for regulators.倾听公众意见并满足其信息需求——将疫苗传播研究结果转化为监管指南。
Br J Clin Pharmacol. 2018 Aug;84(8):1696-1705. doi: 10.1111/bcp.13587. Epub 2018 May 31.
4
Safety Communication Tools and Healthcare Professionals' Awareness of Specific Drug Safety Issues in Europe: A Survey Study.安全通讯工具与欧洲医疗保健专业人员对特定药物安全问题的认知：一项调查研究。
Drug Saf. 2018 Jul;41(7):713-724. doi: 10.1007/s40264-018-0643-5.
5
The Next Generation of Drug Safety Science: Coupling Detection, Corroboration, and Validation to Discover Novel Drug Effects and Drug-Drug Interactions.下一代药物安全科学：结合检测、证实和验证以发现新的药物作用和药物相互作用。
Clin Pharmacol Ther. 2018 Feb;103(2):177-179. doi: 10.1002/cpt.949.
6
Measuring the impact of medicines regulatory interventions - Systematic review and methodological considerations.衡量药品监管干预措施的影响——系统评价及方法学考虑。
Br J Clin Pharmacol. 2018 Mar;84(3):419-433. doi: 10.1111/bcp.13469. Epub 2017 Dec 20.
7
A descriptive review of additional risk minimisation measures applied to EU centrally authorised medicines 2006-2015.对2006年至2015年适用于欧盟集中授权药品的额外风险最小化措施的描述性综述。
Expert Opin Drug Saf. 2017 Aug;16(8):877-884. doi: 10.1080/14740338.2017.1335303. Epub 2017 Jun 7.
8
Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study.FDA 警告和媒体报道后青少年抗抑郁药使用和自杀行为的变化：准实验研究。
BMJ. 2014 Jun 18;348:g3596. doi: 10.1136/bmj.g3596.
9
Post-approval evaluation of effectiveness of risk minimisation: methods, challenges and interpretation.上市后有效性风险最小化评估：方法、挑战与解读。
Drug Saf. 2014 Jan;37(1):33-42. doi: 10.1007/s40264-013-0126-7.
10
Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs.在食品药品监督管理局（FDA）发布关于选择性5-羟色胺再摄取抑制剂（SSRI）导致儿科自杀风险的咨询意见后，对初级保健中成人抑郁症治疗的溢出效应。
Am J Psychiatry. 2007 Aug;164(8):1198-205. doi: 10.1176/appi.ajp.2007.07010007.
Zotero 插件